Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Vatter

Showing results (291-300 of 311) with videos related to

Pageof 32
Sort By:
Journal of Neuro-Oncology|July 21, 2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trialSied Kebir, Christina Schaub, Nina Junold, et al.
Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.
Journal of Neuro-Oncology|July 21, 2023
Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysisJulian P Layer, Motaz Hamed, Anna-Laura Potthoff, et al.
BMC Cancer|November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer CenterMarie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Neuro-Oncology|October 10, 2025
Early Palliative Care for Patients with Glioblastoma: A randomized phase lll clinical trial (EPCOG)Heidrun Golla, Charlotte Nettekoven, Martin Hellmich, et al.
Journal of Neurology|August 14, 2024
Rasmussen's encephalitis: structural, functional, and clinical correlates of contralesional epileptiform activityTobias Bauer, Randi D von Wrede, Suresh Pujar, et al.
Trials|January 20, 2022
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trialThomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, et al.
Neurosurgery|July 22, 2025
Pediatric Intracranial Infections Requiring Neurosurgery: A German Multicenter Analysis of 10-Year Trends Pre-COVID-19 and Post-COVID-19Daniel Dubinski, Sae-Yeon Won, Artem Rafaelian, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|April 1, 2022
Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial: Study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Sylvia Bele, et al.
Neuro-Oncology|April 17, 2021
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastomaMatthias Schneider, Lea Vollmer, Anna-Laura Potthoff, et al.
Pageof 32

Showing results (291-300 of 311) with videos related to

Sort By:
Pageof 32
Journal of Neuro-Oncology|July 21, 2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trialSied Kebir, Christina Schaub, Nina Junold, et al.
Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.
Journal of Neuro-Oncology|July 21, 2023
Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysisJulian P Layer, Motaz Hamed, Anna-Laura Potthoff, et al.
BMC Cancer|November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer CenterMarie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Neuro-Oncology|October 10, 2025
Early Palliative Care for Patients with Glioblastoma: A randomized phase lll clinical trial (EPCOG)Heidrun Golla, Charlotte Nettekoven, Martin Hellmich, et al.
Journal of Neurology|August 14, 2024
Rasmussen's encephalitis: structural, functional, and clinical correlates of contralesional epileptiform activityTobias Bauer, Randi D von Wrede, Suresh Pujar, et al.
Trials|January 20, 2022
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trialThomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, et al.
Neurosurgery|July 22, 2025
Pediatric Intracranial Infections Requiring Neurosurgery: A German Multicenter Analysis of 10-Year Trends Pre-COVID-19 and Post-COVID-19Daniel Dubinski, Sae-Yeon Won, Artem Rafaelian, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|April 1, 2022
Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial: Study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Sylvia Bele, et al.
Neuro-Oncology|April 17, 2021
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastomaMatthias Schneider, Lea Vollmer, Anna-Laura Potthoff, et al.
Pageof 32